Cencora, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Cencora, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Goodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative. Less tangible than almost all Healthcare companies in United States.
- Debt Due Cover Ratio: Debt due within a year is covered 32.9 times by its yearly operating cash. Higher than 92% of Healthcare companies in United States.
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: $3 per $100 of sales comes from others' credit, against $3 from others' credit three years earlier. Less money tied up than 92% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Sep 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
7.0×Over the last 3 years its own operating cash covered its investment spending (capex) 7.0 times.
Higher than 91% of Healthcare companies in United States.
Cash Locked Ratio
−$3Money owed to suppliers is larger than money owed by customers plus stock: $3 per $100 of sales comes from others' credit, against $3 from others' credit three years earlier.
Less money tied up than 92% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
−$0Sales grew 35% in 3 years, but profit fell: $0 less profit per $100 of extra sales.
Lower than 67% of Healthcare companies in United States.
Asset Productivity Ratio
+35% / +35%In 3 years sales changed by +35% while total assets changed by +35%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
32.9×Debt due within a year is covered 32.9 times by its yearly operating cash.
Higher than 92% of Healthcare companies in United States.
Cash Cushion Ratio
−5%Debt, after subtracting cash, equals 5% of its market value (net debt).
Lower than 74% of Healthcare companies in United States.
Tangible Assets Ratio
77%Of every $100 the company owns, $77 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 54% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than almost all Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Cencora, Inc. owes $0.96 for every $1 it owns. Net profit rose 3% in the year to Sep 2025, and shrank 3% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Sep 2025.
P/E ratio
25.1Investors pay $25.1 for every $1 of Cencora, Inc.'s yearly profit, lower than 53% of Healthcare companies in United States.
P/B ratio
21.17The share price is 21.17 times Cencora, Inc.'s book value per share, higher than 94% of Healthcare companies in United States.
Market cap
$64.6 BThe total market value of all of Cencora, Inc.'s shares at today's price (share price × number of shares), larger than 97% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$3.1 BWhat Cencora, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$15.99Net worth divided by the number of shares. The share price of $338.48 is 21.2 times this, which is the P/B above.
Return on equity (ROE)
96.9%Cencora, Inc. earned 96.9% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
Owes vs Owns
0.96×Cencora, Inc. owes $0.96 for every $1 it owns (high), higher than 85% of Healthcare companies in United States.
Dividend yield
0.71%Cencora, Inc. pays 0.71% of its share price as dividends a year, lower than 62% of dividend-paying Healthcare companies in United States.
Revenue growth
+9%Revenue rose 9% in the year to Sep 2025, and grew 10% a year on average over 3 years.
Profit growth
+3%Net profit rose 3% in the year to Sep 2025, and shrank 3% a year on average over 3 years.
Profit margin
0.5%Cencora, Inc. keeps $0 of every $100 of revenue as net profit.
Cash quality
2.5×Cash from Cencora, Inc.'s business was 2.5× its reported profit in the year to Sep 2025 — its profit turned into cash.
Interest cover
9.4×Cencora, Inc.'s operating profit covered its interest costs 9.4 times in the year to Sep 2025.
Cash vs debt
Net debtCencora, Inc. had $3.3 B more debt than cash (net debt) at Sep 2025.
Questions
What is Cencora, Inc.'s P/E ratio?
Investors pay $25.1 for every $1 of Cencora, Inc.'s yearly profit, lower than 53% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Cencora, Inc.: $64.6 B ÷ $3.1 B (30 Jun 2026) = 21.2.
What is Cencora, Inc.'s return on equity?
Cencora, Inc. earned 96.9% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
How much does Cencora, Inc. owe compared with what it owns?
Cencora, Inc. owes $0.96 for every $1 it owns (high), higher than 85% of Healthcare companies in United States.
Does Cencora, Inc. pay a dividend?
Yes. Cencora, Inc. pays 0.71% of its share price as dividends a year, lower than 62% of dividend-paying Healthcare companies in United States.
Is Cencora, Inc.'s revenue growing?
Revenue rose 9% in the year to Sep 2025, and grew 10% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.